4.8 Article

Targeting CXCL12 from FAP-expressing carcinomaassociated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer

Related references

Note: Only part of the references are listed.
Article Medicine, General & Internal

Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma

Omid Hamid et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Article Medicine, General & Internal

Nivolumab plus Ipilimumab in Advanced Melanoma

Jedd D. Wolchok et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Article Medicine, General & Internal

Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer

Julie R. Brahmer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Article Medicine, Research & Experimental

Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma

Jo Eyles et al.

JOURNAL OF CLINICAL INVESTIGATION (2010)

Article Medicine, General & Internal

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

F. Stephen Hodi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

Article Biochemistry & Molecular Biology

HMGB1 release and redox regulates autophagy and apoptosis in cancer cells

D. Tang et al.

ONCOGENE (2010)

Article Pathology

Prognostic Significance of CXCL12 Expression in Patients With Colorectal Carcinoma

Yuri Akishima-Fukasawa et al.

AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2009)

Review Oncology

New approaches for imaging tumour responses to treatment

Kevin Brindle

NATURE REVIEWS CANCER (2008)

Article Medicine, General & Internal

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

L Zhang et al.

NEW ENGLAND JOURNAL OF MEDICINE (2003)

Article Biochemistry & Molecular Biology

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

HD Dong et al.

NATURE MEDICINE (2002)

Article Biochemistry & Molecular Biology

Active movement of T cells away from a chemokine

MC Poznansky et al.

NATURE MEDICINE (2000)